Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Chimeric Toxin Slows Cancer Growth
Disease Discoveries

Chimeric Toxin Slows Cancer Growth

By Will DossJul 6, 2020
Share
Facebook Twitter Email
Karla Satchell, PhD, professor of Microbiology-Immunology and member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was senior author of the study published in Proceedings of the National Academy of the Sciences.

A chimeric toxin slowed tumor growth in mouse models of human breast and colon cancer, according to a Northwestern Medicine study published in Proceedings of the National Academy of the Sciences (PNAS).

The novel compound uses the targeting machinery from diphtheria toxin grafted to a protease that inhibits RAS, a signaling pathway implicated in as many as 50 percent of cancers. While this proof-of-concept might target all human cells, investigators are now modifying the diphtheria machinery to specifically target cancer cells in the hopes of creating an effective therapeutic, according to Karla Satchell, PhD, professor of Microbiology-Immunology and co-senior author of the study.

“We showed that this toxin reduced tumorigenesis and in some cases even shrank tumors,” said Satchell, who is a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. “If we can target this specifically to cancer cells, taking out RAS might take out the cancer.”

Many toxins can be classified as “AB” toxins, made up of an “activity” subunit, which attacks targets and a “binding” subunit, which seeks out and binds to targets. Scientists realized the therapeutic potential of these toxins more than 30 years ago, and replaced the binding subunit of diphtheria toxin with immune antibodies in a bid to fight cancer.

While these compounds did indeed home in on and attack cancer cells, the inefficient targeting meant healthy cells were also attacked, leading to significant negative side effects that limited their use. Attempts to instead attach new activity subunits to the diphtheria binding subunit failed, and scientists turned their eyes towards other possible treatments.

However, recent studies authored by Roman Melnyk, PhD, senior scientist in the Department of Molecular Medicine at the Hospital for Sick Children (SickKids) in Toronto, have shown the binding subunit is in fact malleable, and may offer a new scientific avenue. Melnyk is also co-senior author of the current study.

“For 30 years, nobody worked on it, and it turns out these old papers were wrong,” Satchell said. “Now, our idea is to flip it around. Instead of using highly toxic diphtheria, let’s swap it for something cancer-specific.”

That ‘“something” turned out to be a peptide inhibitor that cleaves RAS, a signaling pathway that when mutated helps cancer cells proliferate. To test the RAS inhibitor’s effectiveness, Satchell, Melnyk and colleagues grafted human breast and colon cancer cells onto mice and administered the chimeric toxin.

Because mice don’t respond to diphtheria toxin, the chimeric toxin trafficked directly to the human cancer cells and slowed tumor growth, demonstrating the effectiveness of the RAS inhibitor.

Now, Satchell and her collaborators are working to modify the binding subunit to only recognize unique receptors found in cancer cells, such as EGFR, which is found in skin cancers.

“There’s a huge amount of research on this,” Satchell said. “There’s no shortage of targets, because drug developers are always trying to target their drugs as specifically as possible.”

If the binding subunit can be modified to traffic only to cancer cells, this chimeric toxin could be a seek and destroy weapon against cancer, Satchell said.

“Now we know it works, it’s well worth our while to go figure out a targeting strategy,” Satchell said.

This work was funded by the Lynn Sage Cancer Research Foundation, Northwestern University Clinical and Translational Sciences (which is supported by NIH/NCATS Award UL1TR001422), the Northwestern Medicine Catalyst Fund, the Robert H. Lurie Comprehensive Cancer Research Center, NIH grants R01CA152601, R01CA152799, R01CA168292, R01CA214025, the Avon Breast Cancer Foundation, the Zell Family Foundation, the Chicago Biomedical Consortium, the Searle Funds at The Chicago Community Trust, the SickKids Proof-of-Principal Funding and the Canadian Institutes of Health Research 366017, the PanCan/FNLCR Fellowship and the SickKids Restracomp Fellowship.

Cancer Genetics Research
Share. Facebook Twitter Email

Related Posts

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Comments are closed.

Latest News

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022

Hospitals Bound to Patient Safety Rules that Aren’t all Backed by Evidence

Jun 24, 2022

Identifying Protein Interactions that Promote Cancer Growth

Jun 24, 2022

Combination Treatment May Improve Quality of Life in Kidney Cancer

Jun 23, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.